Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing

Executive Summary

Gilead's sofosbuvir/velpatasvir combination Epclusa and Merck's grazoprevir and elbasvir combo Zepatier are on course for approval in Europe for treating hepatitis C, but analysts say Gilead's two-drug therapy has the better commercial prospects of the two.

Advertisement

Related Content

HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates
Merck Defends Its Offensive Strategy For Keytruda
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register